Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts ...
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today and set a price ...
Brand.com’s are connecting HCPs to information, with fewer hoops to jump through, courtesy of new digital tools promising to ...
NAARDEN, the Netherlands and MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical ...
NewAmsterdam Pharma's obicetrapib shows promise in lipid management with successful Phase 3 trials, strong cash reserves, and a differentiated commercial strategy. Despite past CETP inhibitor ...
NewAmsterdam Pharma (NASDAQ:NAMS) is a biotech company with one lead asset, namely obicetrapib which the company aims to develop for a number of indications related to cardiovascular risk.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adaptimmune Therapeutics (ADAP – Research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback